Professor & Senior VP- Neuroscience Drug DiscoverySanford Burnham Prebys Medical Discovery Institute
Neuroscience, Alzheimer's Disease, Multiple Sclerosis (MS), Parkinson's Disease
Associate Professor of Neurosurgery, Radiation oncUniversity of California, Los Angeles (UCLA), Health Sciences
Neurosurgery, Neuroscience, Brain Tumor, Hearing, Balance, Radiosurgery, UCLA, David Geffen School of Medicine at UCLA
Isaac Yang, M.D., is a nationally renowned neurosurgeon specializing in brain tumors, superior semicircular canal dehiscence (SSCD), and skull base brain surgery at UCLA. Yang is a board-certified neurosurgeon and director of medical student education for the UCLA Department of Neurosurgery; an associate professor of neurosurgery, head and neck surgery, and radiation oncology at the David Geffen School of Medicine at UCLA, and a principal investigator at the UCLA brain tumor laboratory. Yang is highly sought out by peers, patients and the media for his expertise in neurological diseases and brain health. He has made multiple TV appearances on Good Morning America, CBS' The Doctors, Dr. Drew LifeChangers, and several national news outlets. Originally from Lodi, Calif., Yang developed an interest in neurobiology as an undergraduate. He earned his bachelor’s degree with Phi Beta Kappa from the University of California, Berkeley. His training followed with a medical degree from the David Geffen School of Medicine at UCLA. Yang completed a neurological surgery residency at the University of California San Francisco, as well as an NRSA NIH-funded F32 postdoctoral brain tumor research fellowship. Yang’s clinical focus has been primarily on brain tumors, both glioblastoma and skull base tumors. His research efforts have examined antigen expression and manipulation of the immune response to glioblastoma. His work was recognized by a UCSF Clinical and Translational Scientist Training Award and the CNS Dandy Clinical Research Fellowship. Yang has been the recipient of several distinguished regional and national awards, including the UCSF Medical Center 2010 Exceptional Physician Award, the AANS Integra Brain Tumor Research Award, San Francisco Neurological Society Edwin Boldrey Award for Basic Science Research, American Academy of Neurological and Orthopedic Surgeons Research Award, Kaiser Award for Clinical Research, the national AANS Leksell Radiosurgery Award, and the Tumor Section Ronald L. Bittner Award on Brain Tumor Research. Yang has published more than 150 publications in peer-reviewed journals and authored more than half a dozen book chapters. At UCLA, he is investigating the use of nanoparticles and nanotechnology for their application in brain tumor immunotherapy and vaccines. Dr. Isaac Yang is dedicated to improving the care and treatment of all patients undergoing neurosurgery. If interested please follow Dr. Yang on Facebook at Isaac Yang UCLA Neurosurgery or find his most recent book, Service Minded Physician, on Amazon.
Jocelyn Read is an astrophysicist who studies neutron stars — the remnant cores of dead stars that didn't quite have enough mass to end up as black holes. A leading binary neutron star expert, she focuses on how matter behaves at the extremely high densities inside neutron stars and how this might be measured from astronomical observations of X-rays, gamma-ray bursts and gravitational waves. She and her students work to understand and model how neutron stars interact, collide and radiate energy to learn more about their structure and composition. Read joined Cal State Fullerton in 2012 and has received numerous grants for her research. Most recently, she was awarded nearly $1 million from the National Science Foundation to lead a project to recruit and support underrepresented students, in particular Latino students, in gravitational-wave science. The grant supports CSUF and Citrus College students engaged in undergraduate research, as well as CSUF alumni in the doctoral program in gravitational-wave astrophysics at Syracuse University. A native of Calgary, Alberta, Canada, Read earned her doctorate in physics from the University of Wisconsin-Milwaukee and a bachelor's degree in mathematics and physics from the University of British Columbia in Vancouver. She completed postdoctoral work at the Albert Einstein Institute in Germany and at the University of Mississippi. Read, a member of the LIGO Scientific Collaboration, serves as associate director of CSUF's Gravitational-Wave Physics and Astronomy Center. She is the recipient of the 2017 "Women of the Year" award in the category of science and technology from state Sen. Josh Newman. For additional CSUF materials and resources, please visit these websites: • CSUF News Center: http://news.fullerton.edu • CSUF Gravitational-Wave Physics and Astronomy Center: http://physics.fullerton.edu/gwpac/ • CSUF Scientists Contribute to First Discovery: http://news.fullerton.edu/gravitational-waves/default.aspx
Director, UCLA Steve Tisch BrainSPORT ProgramUniversity of California, Los Angeles (UCLA), Health Sciences
Concussion, concussion and football, traumatic brain injuries, Youth, Neuroplasticity, post-traumatic epilepsy, concussion and sports, Sports-Related Head Injury, Brain Development, helmet studies, Neuroimaging, Genetic Markers
Before joining UCLA, Giza worked on the Yosemite Search and Rescue team. In 2011, he traveled to Afghanistan as a civilian advisor to the U.S. Department of Defense. He co-chaired the American Academy of Neurology committee that developed an evidence-based practice guideline for the management of sports concussions from 2009-2013. He currently serves on advisory committees for traumatic brain injuries/concussion with the U.S. Centers for Disease Control, National Collegiate Athletic Association, Major League Soccer and U.S. Soccer Federation. He has been a clinical consultant for the National Football League, National Hockey League and Major League Soccer.
Assistant Professor of Health and Wellness StudiesBinghamton University, State University of New York
Nutrigenomics, Neurodegeneration, Nutrition, Mental Distress, Microbiota, Food
Begdache’s research interests include nutrigenomics and nutrigenetics, neurodegeneration, nutrition and mental distress, and microbiota. She teaches several courses, including Human Nutrition and Metabolism, Introduction to Cell and Molecular Biology, Principles of Cell Biology, Molecular Genetics, and Pathophysiology of Nutrition-Related Diseases. Begdache was featured by publications such as Bustle and The New York Post for her researching showing a connection between food and mood, and she wrote a piece for The Conversation on the hefty price of study drug misues on college campuses.
Dr. Crotty received his B.S. in Biology from the Massachusetts Institute of Technology (MIT) in 1996. He also received a B.S. in Writing from MIT the same year. Dr. Crotty undertook graduate work in virology at the University of California, San Francisco in the Program in Biological Sciences. There he discovered the mechanism of action of the antiviral drug ribavirin, widely used to treat chronic hepatitis C infections. Dr. Crotty earned his Ph.D. in Biochemistry and Molecular Biology in 2001. He then pursued postdoctoral work at the Emory University Vaccine Center with Dr. Rafi Ahmed from 2001 to 2003, studying aspects of the generation and maintenance of immune memory after viral infections. In 2003, he accepted a faculty position at LJI. The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science 2009). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology 2011). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annualAmerican Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012. Dr. Crotty is also the author of Ahead of the Curve, a biography of Nobel laureate scientist David Baltimore, published in 2001, and reviewed in The Wall Street Journal, Nature, The Washington Post, The Journal of the American Medical Association (JAMA), Nature Medicine, and Discover Magazine.
Dr Katy Hayward is one of the leading political sociologists on the island of Ireland, and is a Reader in Sociology, and Senior Research Fellow at the Senator George J. Mitchell Institute for Global Peace, Security and Justice at Queen’s University Belfast. Dr Hayward’s research focuses on conflict/post-conflict transitions and is actively interdisciplinary, traversing fields of border studies, conflict studies, European studies, and Irish studies. This means that she is particularly well-placed to speak about the implications of Brexit for the island of Ireland, and Northern Ireland in particular, European integration, political violence, and the application of discourse analysis.
Professor, Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO. Research has focused on neural mechanisms of adaptation to alcohol, including tolerance and dependence. Identified a role of peptide hormones and brain growth factors to modify alcohol tolerance. Discovered that one subtype of glutamate receptor, the NMDA receptor, is very sensitive to alcohol, and that increases in NMDA receptor function are involved in alcohol dependence. This work has led to many further studies by others that focus on the role of the brain glutamate systems in addiction to alcohol and other drugs. Currently focus on systems genetic analysis, using "big data" to understand the genetic contribution to alcohol-related and other complex behaviors.
I have almost 40 years of experience in the field of alcoholism research, with much of my work focusing on the molecular sites and mechanisms of alcohol action in brain. My group has extensive experience with mouse behavioral models of alcohol consumption and dependence and was involved in some of the initial studies of the neuroimmune basis of alcohol dependence. Profiling brain gene expression is key to understanding addiction, and we were among the first to study the human brain transcriptome. We have implemented microRNA profiling and next-generation sequencing to extend our studies of molecular remodeling by alcohol in human and mouse brain. We study the genetic overlap in human alcoholics and animal models of alcohol dependence and examine the neurobiological systems involved. My research encompasses the fields of genomics, behavior, systems biology, and bioinformatics. Overall, my work has combined functional, structural, behavioral, and genomic approaches to define sites of alcohol action. Currently, I am Associate Director of the Waggoner Center for Alcohol and Addiction Research at The University of Texas at Austin and previously served as Director for 20 years. I am also the Consortium Director for the Integrative Neuroscience Initiative on Alcoholism (INIA)-Neuroimmune, where our goal is to identify and test candidate drugs that may be repurposed to treat alcohol use disorders.
Assistant ProfessorTexas State University
Clinical Psychology, Neuropsychology, Neuroscience, Psychopathology
Dr. Amitai Abramovitch is an Assistant Professor at the Department of Psychology at Texas State University. Dr. Abramovitch is a Licensed Clinical Psychologist and received his MA degree in Clinical Neuropsychology from the Academic College of Tel-Aviv University and obtained his Ph.D. in Psychology from Tel-Aviv. He has extensive clinical experience in individual and couple psychotherapy, parent training, and neuropsychological assessments, both from his work in national centers, hospitals, and private practice.
Erica Ollmann Saphire, Ph.D. is a Professor of the La Jolla Institute for Immunology and one of the world’s leading experts in pandemic and emerging viruses, such as Ebola, Marburg and Lassa. Dr. Saphire directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), an NIH-funded Center of Excellence in Translational Research. The VIC unites 43 previously competing academic, industrial and government labs across five continents to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses. Dr. Saphire's research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for developing antibody-based treatments. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses. A recent discovery revealed why neutralizing antibodies had been so difficult to elicit against Lassa virus, and provided not only the templates for the needed vaccine, but the molecule itself: a Lassa surface glycoprotein engineered to remain in the right conformation to inspire the needed antibody response. This molecule is the basis for international vaccine efforts against Lassa. Dr. Saphire is the recipient of numerous accolades and grants, including the Presidential Early Career Award in Science and Engineering presented by President Obama at the White House; the Gallo Award for Scientific Excellence and Leadership from the Global Virus Network; young investigator awards from the International Congress of Antiviral Research, the American Society for Microbiology, American Society for Biochemistry and Molecular Biology, and the MRC Centre for Virus Research in the United Kingdom; the Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, and the Surhain Sidhu award for the most outstanding contribution to the field of diffraction by a person within five years of the Ph.D. Dr. Saphire has been awarded a Fulbright Global Scholar fellowship from the United States Department of State and a Mercator Fellowship from the German research foundation, Deutsche Forschungsgemeinschaft, to develop international collaborations around human health and molecular imaging through cryoelectron microscopy. Dr. Saphire received a B.A. in biochemistry and cell biology and ecology and evolutionary biology from Rice University in Houston, Texas, and a Ph.D. in molecular biology from Scripps Research. She stayed on at Scripps Research as a Research Associate to conduct postdoctoral research and rose through the ranks to become a Professor in the Department of Immunology and Microbiology. In early 2019, Dr. Saphire joined La Jolla Institute for Immunology to establish a molecular imaging facility for cryo-electron microscopy (cryo-EM) at the Institute. The extremely detailed images produced by cryo-EM reveal precisely how essential mechanisms of the immune system operate.
Professor of Biomedical AnthropologyBinghamton University, State University of New York
Disease, Neurodegenerative Disorder, Amyothrophic Lateral Sclerosis, Parkinson's Disease, Alzheimer's Disease, Food Chain, Obesity, Malaria
Garruto’s research interests include natural experimental models of disease, using both field and laboratory approaches. His cross-disciplinary research and interests include studies of neurodegenerative disorders including amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease, food chain disorders, health transition studies, obesity and bionutrition, malaria, Lyme and other tick-borne diseases, and prion diseases, especially chronic wasting disease.
Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise. With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health. Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium. As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally. Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.
Medical Director, Cellular Immunotherapy Integrated Research Center at Fred HutchFred Hutchinson Cancer Research Center
CAR T-cell therapy, Immunotherapy, Chimeric antigen receptor T-cell, Lymphoma, Leukemia, Myeloma, cancer immunotherapies, Blood Cancers, ofatumumab, Arzerra, Hematopoietic
Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T’s and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation. He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market – one that has transformed the treatment of certain leukemias and lymphomas. He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT. Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous “graft-vs-host” effects on normal tissues. Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra®) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant “conditioning” or as “maintenance” to extend remissions after allogeneic transplantation. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.
Dr. Andrew M. Evens is a physician-scientist at the Rutgers Cancer Institute of New Jersey, where he is Associate Director for Clinical Services and Director of the Lymphoma Program. In addition, he is the Medical Director of the Oncology Service Line for the RWJBarnabas Health system. Dr. Evens completed a Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, where he was also Director of Translational Therapeutics. Prior to his Rutgers Cancer Institute appointment, Dr. Evens served as Chief of the Division of Hematology/Oncology at Tufts Medical Center and as Director of the Tufts Cancer Center in Boston, MA. Dr. Evens is an associate editor for the British Journal of Haematology and serves on the editorial board for the Journal of Clinical Oncology. He is a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and has been a member of several clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. Dr. Evens is also an elected member of the Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and he is involved in multiple national and international educational forums and events. I completed a prior fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where I also remained as a faculty member altogether for 10 years. Most recently, I served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine. My clinical expertise and research interests are fully dedicated to the field of lymphoma (i.e., Hodgkin lymphoma and non-Hodgkin lymphoma). Over the past 15+ years, I have been the principal investigator of more than 80 national and international cancer clinical trials that have included phase I, II, and III studies, many which have been “investigator-initiated” trials studying new and novel targeted agents for the treatment of lymphoid malignancies. In addition to my clinical research, I also manage a translational laboratory studying the biology of lymphoma and to discover new and novel treatments for patients. Collectively, my research has been continuously funded by the National Institutes of Health (NIH) and the NCI since 2005. This has resulted in 200+ research abstracts at national and international cancer research symposiums, 150+ manuscripts in peer-reviewed publications, and 20+ book chapters all with an emphasis on the biology, prognosis, and treatment of lymphoma. My involvement in the advancement of cancer research has also included leadership roles in academic journals, symposiums, cancer advocacy groups, and international committees. I was an associate editor for the British Journal of Haematology and on the editorial board for the Journal of Clinical Oncology and am the inaugural editor in chief for the open access journal, eJHaem. I am a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and I have been a member of several additional clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. Furthermore, I am Co-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group and am honored to be an elected member of the North American Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and a member of the Board of Trustees for the Leukemia & Lymphoma Society (LLS) New Jersey Chapter. Finally, I am involved and help lead a multitude of regional, national, and international educational forums and events. Positions: Associate Director for Clinical Services at Rutgers Cancer Institute of New Jersey Medical Director of the Oncology Service Line, RWJBarnabas Health Director, Lymphoma Program, Division of Blood Disorders Clinical Expertise: Hodgkin lymphoma, non-Hodgkin lymphoma (all types), chronic lymphocytic leukemia, and autologous hematopoietic stem cell (or bone marrow) transplantation. Research Interests: Lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma) Chronic lymphocytic leukemia and other lymphoid malignancies Clinical trials Translational studies, including lymphoma biology and drug discovery Systems biology and biomarker analyses Lymphoma epidemiology Health Outcomes, including Pharmacovigilance and Decision Making I am thrilled to be a member of the Rutgers Cancer Institute of New Jersey (CINJ) as the Associate Director for Clinical Services, Medical Director of the Oncology Service Line for RWJBarnabas Health, and Director of the Lymphoma Program. Rutgers Cancer Institute is unique in that it is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center. Our mission is to deliver integrated cancer care across the health system with access to academic expertise and innovative cancer therapies not available elsewhere in the state.
Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics. Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. Clinical Expertise: Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.
Clinical Professor of Global Shifts and the Fourth Industrial RevolutionThunderbird School of Global Management
Artificial Intelligence, Machine Learning, Business, technology and society, technology acceleration, Technology, Technological Entrepreneurship, Technology Transfer and Commercialization, Global Business, global business strategy, AI, Algorithms, Algorith
Dr. Mark Esposito is recognized internationally as a top global thought leader in matters relating to The Fourth Industrial Revolution, the changes and opportunities that technology will bring to industry. Mark has held numerous senior positions at prestigious Institutes. He has been a member of the teaching faculty at Harvard University’s Division of Continuing Education where he has taught Economic Strategy and Competitiveness. He also has served as a Co-Leader at the Institutes Council for the Microeconomics of Competitiveness program (MOC) at Harvard Business School. Besides being a Professor at Thunderbird/ASU, Mark has been a Professor of Business & Economics at Hult International Business School, globally. He is an appointed Research Fellow in the Circular Economy Center, at the University of Cambridge's Judge Business School. He is also a Fellow for the Mohammed Bin Rashid School of Government in Dubai. Mark is the Co-Founder and Chief Learning Officer of Nexus Frontier Tech, an AI Studio, dedicated to the productions of AI solutions. He is a prolific author and his articles can be found on ResearchGate and his books on Amazon. Mark serves as a global expert for the World Economic Forum. He is the co-author of the best seller Understanding How the Future Unfolds: Using DRIVE to Harness the Power of Today's Megatrends. The framework contained therein was nominated for the CK Prahalad Breakthrough Idea Award by Thinkers50, the most prestigious award in business thought leadership. His latest book, The AI Republic (2019) explores the nexus between humans and intelligent automation under the dome of the 4IR. Mark holds a Ph.D. in Business and Economics from the International School of Management in Paris/ New York and an Executive Doctorate in Business Administration from Ecole des Ponts ParisTech in Paris. Areas of Expertise: Fourth Industrial Revolution Megatrends Artificial Intelligence/Digital Leading change Competitiveness Economic Strategy Growth and Competitive Strategy Languages of Instruction: English French German Italian Spanish Education Executive Doctorate of Business Administration, Ecole des Ponts Paris Tech PhD in Business and Economics, International School of Management, Paris/New York B.A and M.A in Social Sciences, University of Turin, Italy